دانلود کتاب داروهای مصنوعی جدید در میگرن

Novel Synthetic Drugs in Migraine represents a new chapter in the Headache Book Series saga, an educational project created and endorsed since its conception within the European Headache Federation. This series offers the reader an organized summary of the news in the headaches area, covering the clinical and therapeutic aspects across the board, always with an agile usability. This volume organizes and presents to the reader the latest therapeutic opportunities for the treatment of migraine: gepants and ditans, molecules that are positioned in the management of either the preventative or acute treatment phases, or in a case covering them both. The complexity of migraine therapy has recently been simplified by the recognition of a strategic target such as the calcitonin gene-related peptide which is currently the focus of preventative therapies. The new pharmacological class of gepants, such as atogepant, rimegepant, ubrogepant, and vazegepant, antagonists of the calcitonin gene-related peptide receptor, aims at the same target of current migraine preventatives and acute therapies but at the same time offers an easier treatment modality for optimal therapeutic adherence in prevention. The other therapeutic class, the ditans, 5-HT1F receptor agonists represented now by lasmiditan, offers a greater safety than the available drug class of the triptans, opening the door to all migraine sufferers who could not have access to previous therapies for the treatment of the acute crisis, which targeted the 5-HT1B/1D receptor.